Please enable JavaScript.
Coggle requires JavaScript to display documents.
BREST CANCER TREATMENT - Coggle Diagram
BREST CANCER TREATMENT
DRUG
Bone-modifying agents
Bisphosphonates:
Inhibits osteoclast activity induced by tumors,
decreasing bone resorption
-
-
-
Denosumab (Prolia) Monoclonal antibody with affinity for nuclear factor kapppa ligand prevents osteoclast formation, leading to decrease bone resoption
Chemotherapy
Alkylating agents:
Covalently binds to DNA, interfering with its normal
functions
-
-
-
Taxanes: Inhibits microtubule disassembly during mitosis,
preventing cell division
-
-
Endocrine
therapy
Aromatase inhibitors: Inhibit the enzyme aromatase, which prevents the conversion of androstenedione to estrone, and of testosterone to estradiol
-
-
-
-
immunotherapy
ERBB2-targeted monoclonal antibodies: Monoclonal antibody that targets the extracellular domain of ERBB2, thereby preventing activation of downstream signaling pathways
-
-
Neratinib (Nerlynx) Irreversible tyrosine kinase inhibitor of ERBB2 that
reduces downstream signaling pathways
Surgery & Radiation
Stage 0 In situ, noninvasive
-
Stage I and IIa, IIb Early invasive
Surgery: Commonly lumpectomy plus sentinel lymph node biopsy mastectomy may be needed for larger tumors or because of patient choice
Radiation: Yes, if lumpectomy or high-risk, node- positive disease with mastectomy
-
-